Metabolic dysregulation in melanoma: cause or consequence?

Rizwan Haq

doi:10.1158/2159-8290.CD-14-0173

Metabolic dysregulation in melanoma: cause or consequence?

Cancer Discov. 2014 Apr;4(4):390-1. doi: 10.1158/2159-8290.CD-14-0173.

Author

Rizwan Haq¹

Affiliation

¹ Center for Melanoma, Massachusetts General Hospital Cancer Center and Cutaneous Biology Research Center, Harvard Medical School, Boston, Massachusetts.

PMID: 24706656
DOI: 10.1158/2159-8290.CD-14-0173

Abstract

Parmenter and colleagues identify molecular pathways by which BRAF-MAPK signaling regulates glycolysis in melanoma, suggesting novel approaches to target these metabolic dependencies.

Publication types

Comment

MeSH terms

Glycolysis / drug effects*
Humans
Melanoma / genetics*
Protein Kinase Inhibitors / pharmacology*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics*

Substances

Protein Kinase Inhibitors
BRAF protein, human
Proto-Oncogene Proteins B-raf